je.st
news
Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea
2015-09-08 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & SEOUL, South Korea First Product from Global Partnership to Deliver High-Quality Biosimilars to Help Meet Needs of Patients and Healthcare Systems Worldwide KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orSamsung BioepisMedia:Jamyung Cha, (82) 32-455-6137orInvestors:Sungjoon Park, (82) 32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
korea
samsung
approval
Category:Biotechnology and Pharmaceuticals